needs a systemic approach. 5 Macrocytosis can be seen in many hematological and non-hematological disorders and more than one cause may co-exist in an individual. Serum vitamin B 12 and folic acid tests are routinely ordered but they are limited by their low sensitivity and specificity. [5] [6] [7] [8] Methyl malonic acid and homocysteine levels, though sensitive is costly and not available in all places. This study was done to analyse the clinical, haematological and biochemical parameters in macrocytic anemia and to study the difference between megalobalstic and nonmegaloblastic anemia in these parameters.
METHODS
A prospective cross-sectional descriptive study was conducted for a period of 18 months on adult and pediatric cases presenting with macrocytosis to the department of pediatrics and General medicine of Sir Sunderlal Hospital, Banaras Hindu University, Uttar Pradesh, India.
Cases with age >12 years having MCV≥100fl at presentation and cases with age ≤12 years having MCV more than two standard deviations for that particular age group were taken into study. Those cases who were recently transfused and those already on hematinic therapy were excluded from the study. A detailed clinical history and thorough physical examination was done in all cases. Complete hemogram for all patients were taken from Mindray BC 3000 and 5000 automated hematology analyzers (manufactured in China). The analyzer has been standardized with internal and external quality control.
External quality control was done regularly using samples from BIO-RAD Liquicheck -hematology 16 controls manufactured by BIO -RAD, Irvine, CA, USA. Peripheral blood smear and reticulocyte count was done in all cases. Bone marrow aspiration and biopsy were done in necessary cases. Biochemical parameters including bilirubin levels, serum iron, TIBC and serum LDH were done in all cases using flexor open analyzer (manufactured in USA) in which internal control was done using manufacturer control and external control was done from Christian Medical College, Vellore samples. Thyroid function tests, vitamin B 12 and folate assays, Ultrasound examination and coombs test were done wherever necessary.
A provisional diagnosis was made and patients were classified into megaloblastic and non-megaloblastic group. Patients with low vitamin B 12 and folate levels, megaloblastic erythropoiesis, dysplasia and blastoid cells were initially placed in the megaloblastic group. A trial of hematinic therapy with vitamin B 12 and folic acid was given and response was seen after 1 week, 2 week and after 1 month. Response was seen with reticulocyte count, CBC reports and serum LDH values. Those who did not respond to the treatment were further evaluated and diagnosis was reclassified. Observations were recorded and analysis was done using SPSS V.19 software and medcalc software. p values were calculated by Fisher's exact test or Mann Whitney U test wherever necessary.
Ethical clearance
This study has been approved by the Institute Ethical Committee Board (Institute of Medical Sciences, BHU) and therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All studies followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008(5). Informed consent have been taken from all patients involved in the study.
RESULTS
100 cases of macrocytosis were included in the study. Out of 100 cases, 38% had megaloblastic anemia and 62% had non-megaloblastic macrocytosis. Primary bone marrow disorders (46%) were the most common cause of macrocytosis in our study. This category included acute and chronic leukemia's, aplastic anemia, multiple myeloma, myelofibrosis and myelodysplastic syndrome. The various causes of macrocytosis in our study are detailed in Table 1 . 
Haematological and biochemical parameters
Though most of the cases (98%) presented with anemia, 2 cases did not have anemia. One case had alcohol induced macrocytosis and the other case was drug induced (hydroxyurea). Skin pigmentation in the knuckles and fingers was seen in 8 cases (21.1%) of megaloblastic anemia and was significantly associated with this group (p = 0.0011). Icterus was present in 19 cases (50%) of megaloblastic anemia and was significantly associated with it and glossitis was seen exclusively in this group. In megaloblastic anemia 5 cases (13.0%) had fundal abnormalities in the form of bilateral fundal bleeds (5.2%), Roth spots (5.2%), and splinter hemorrhages (2.6%). The median value in the non-megaloblastic group was 497.50IU/L with the interquartile range of 381-805IU/L. 4 outliners were present in which one case had very high value of 4470IU/L, this patient had hemolytic anemia.
The other cases were aplastic anemia with PNH (1902.5IU/L), CML in chronic phase (1725IU/L) and autoimmune hemolytic anemia (1508IU/L) ( Figure 2 (Table  4) .
Serum bilirubin was raised in 27 cases of megaloblastic anemia (71.1%) with a mean value of 2.83mg/dl and a standard deviation of 1.34mg/dl. The other findings seen less frequently were tear drop cells, target cells and schistiocytes but they were more commonly associated with megaloblastic group. ROC curve analysis was done for MCV values and LDH values to get a cut-off value which can be used as screening tests in macrocytic anemia to differentiate between megaloblastic and non-megaloblastic macrocytic anemia. ROC Curve analysis for serum LDH values gave a criterion value of >1345.2 U/L for megaloblastic anemia (Table 5) , at which the sensitivity was 92.11% specificity was 93.55 % with a positive predictive values of 87.5% and an accuracy of 92%.
Figure 4: ROC curve for MCV values.
The area under the curve was 0.966 and the p value was <0.0001 ( Figure 3) . From the chart, it is inferred that as patient's LDH value rises above 1345.2U/L, there is more probability of having megaloblastic anemia than nonmegaloblastic anemia and cases having serum LDH >4470U/L will most probably not have nonmegaloblastic macrocytosis. ROC curve analysis for MCV values gave a criterion of >121fl for megaloblastic anemia (Table 6) , at which the sensitivity was only 44.7% but specificity was 95.2% with a positive predictive value of 80.95% and an accuracy of 75%. The area under the curve was 0.743 and the p value was <0.0001 ( Figure 4 ). From this curve, it is inferred that cases having MCV>126.8fl will probably not have nonmegaloblastic macrocytosis. When LDH>1345.2U/L or MCV >121fl was taken as a criteria along with Reticulocyte count <2%, the sensitivity was 92.1%, specificity was 93.5%, positive predictive value was 89.7%, negative predictive value was 95%, and accuracy was 93%. Since the sensitivity is 92.1% and specificity is 93.5%, all three parameters combined together can be used as screening test to distinguish between the 2 groups of macrocytic anemia (megaloblastic and non-megaloblastic) and further evaluation can be done depending upon the categorization (Table 7) . 
DISCUSSION
The incidence of macrocytosis has varied from 1.7 to 3.6% in several reports. [1] [2] [3] [4] Though macrocytosis is a common finding seen with the use of automated counters and presents as a common clinical problem, proper evaluation protocols have not been established. The etiology and demographic profile varies among various western and Indian studies. Drug therapy, Vitamin B12 and folate deficiency, alcohol abuse were described as common causes of macrocytosis. 4, 5, [9] [10] [11] [12] But, in present study primary bone marrow disorders was the most common cause. This variation might be due to the difference in the selective criteria (Mcphedran et al [9] used MCV>115fl, Unnikrishnan et al used MCV>95fl) used along with varied environmental and demographic factors. 10 The various studies on macrocytosis are listed in the Table 8 . Savage et al stated that most patients with megaloblastic erythropoiesis and primary bone marrow disorders were 70 years of age or older, but in discordance to this study, mean age at presentation in our study was between 20-40 years of age. 5 The lowered mean age at presentation in megaloblastic anemia may be due to increased demand during growth spurt and puberty. There was female preponderance in megaloblastic anemia in our study which was similar to the study conducted by Khanduri U and Sharma A. 14 Symptoms associated with anemia, history of jaundice, neurological manifestations and bowel disturbances were similar to other studies. 10, 14 Icterus and skin pigmentation were significantly associated with megaloblastic anemia which was similar to the finding of Unnikrishnan et al. 10 The presence of fundal abnormalities as seen in our case has been reported in anemia by few authors. [15] [16] [17] The mean haemoglobin in present study was 5.06g/dl with standard deviation of 2.48g/dl which was similar to Unnikrishnan V et al where the mean Hb was 5.6g/dl with standard deviation of 2.12g/dl. 85% of the patients had severe anaemia with the haemoglobin of ≤7g/dl. In a study by Davidson RJL et al in 1978 with the criteria of MCV>100fl, no cases had haemoglobin <7g/dl. 1, 10 They also found that the severity of macrocytosis increased in proportion to the degree of anaemia. But in our study as well as Unnikrishnan V et al study, no such significant increase could be found (p value = 0.234). The mean MCV in the whole series was 113.31±9.36fl which is much higher than that of Davidson et al and Unnikrishnan V et al. 1, 10 The difference between means of MCV between megaloblastic and non-megaloblastic group was significant with those of megaloblastic group having higher MCV than the non megaloblastic group. Majority of the cases in our study had an MCV between 100-110fl.
So, if we would have taken the cut-off as 115fl as Mcphedran et al, lot of cases would have been missed. Savage et al stated that though MCV values >110fl were seen commonly in patients with megaloblastic anaemia, this degree of MCV elevation was also noted in about 1 in every 3 patient in other disorders. 5, 9 But if MCV exceeds 120fl, megaloblastic erythropoiesis was most likely. In our case too, we found that when MCV was between 110-120fl, almost equal number of cases were present in both the groups, the probability of a case being megaloblastic increased when the MCV was >120fl.Also, they found that when MCV was >120fl, the specificity for diagnosing the case as megaloblastic was 98.6%.
In present study, it was found that the specificity for megaloblastic anaemia at MCV>121fl was 95.16% and this was comparable with the above mentioned study. So, if the MCV>121fl, there is 95% chance that the disease is not a non-megaloblastic. Study found a weak positive correlation (r = 0.324) between MCV and serum LDH, which was significant at 0.01 level. There was a significant difference between means of serum LDH between megaloblastic and non -megaloblastic group.
The maximum value of serum LDH was 19740 IU/L which was 54 times the normal value. Values as high as 28,125 units/L have been reported and the serum LDH values reduced after treatment. 18 A correlation between reticulocytosis and decreasing LDH activity, followed later by rise in haemoglobin has been found in few studies. 19, 20 In present study too, there is a significant difference between LDH values before and after treatment. Jaswal et al stated that raised serum LDH levels were seen in all types of macrocytic anaemia, but serum total LDH values >3000IU/L are diagnostic of megaloblastic anaemia and values between 451-3000 IU/L can be seen in megaloblastic anaemia with early megaloblastic change, dimorphic anaemia and hemolytic anemia. 21 Emerson et al found that the relationship between Hb and serum LDH is not linear. 22 The activity of this enzyme increased disproportionately when anaemia was very severe. They also found that the serum LDH decreases after treatment and suggested that post treatment serum LDH measurement is a good and accurate method for assessing early response to treatment. The elevated serum LDH was due to ineffective hematopoiesis in bone marrow, and not due to the peripheral hemolysis.
Savage et al found that LDH elevations>220IU/L were not specific or sensitive for megaloblastic anaemia. But when LDH >1000U/L were taken, they got sensitivity of 22.2%, specificity of 97.5%, positive predictive value of 36.4% and negative predictive value of 95.1%. 5 In present study, we found that when serum LDH was taken as >1345.2 IU/L (criterion value of ROC curve), the sensitivity was 92.1%, specificity was 93.5% with positive predictive value of 87.5% and a negative predictive value of 95% and a total accuracy of 92%.
When LDH value >1345.2 IU/L or MCV >121fl were taken along with corrected reticulocyte count <2%, the sensitivity and specificity became >90%. So, this criterion can be used as a screening test to differentiate the two groups and further investigation can be done according to the categorization.
Two cases of megaloblastic anaemia had increased blastoid cells in the marrow but those patients responded to treatment. Cases of megaloblastic anaemia having blastoid changes have been reported. Aitelli et al had stated that Vitamin B12 deficiency can cause profound alterations in the bone marrow and may mimic acute leukaemia or myelodysplasia. 23 However, after further studies, they were both found to have vitamin B 12 deficiency, and parenteral vitamin B 12 administration resulted in normalization of the bone marrow. So, a trial of Vitamin B 12 and folic acid therapy should be given before labelling a case as myelodysplasia.
12 cases in present study, which initially showed megaloblastic erythropoiesis in bone marrow were given treatment with B 12 and folic acid and was followed up. They didn't respond to treatment even after 1 month of therapy and repeat marrow aspirations were done in these patients. All of them showed megaloblastic erythropoiesis with features of dysplasia in one or more lines with increased number of blasts. When evaluated retrospectively these patients had only mild increase in serum LDH levels when compared to their megaloblastic anaemia counterpart.
With the advent of automated cell coulters, the red cell indices form an intergral part of diagnosis. Abnormally high values of MCV are common, but their precise clinical significance may be difficult to establish. With a step -wise diagnostic approach, a definitive diagnosis can be reached in most cases. In a resource limited set up, where facilities to measure vitamin B12 and folic acid are not available, a trial of hematinic therapy can be given to those presenting with typical clinical features along with raised MCV and moderate to markedly elevated serum LDH and peripheral blood findings (anisopoikilocytosis, macrocytes, macroovalocytes, hypersegmented neutrophils) and reduced to normal reticulocyte count. Response can be assessed using serum LDH, CBC and reticulocyte count. Those not responding to therapy can be further evaluated.
